This week in Drug Discovery (12-16 October)
News round-up for 12-16 October 2026 by Megan Thomas, Multimedia Editor at DDW.
This week’s news roundup covers the upcoming Drug Discovery Innovators & Investors Conference in London, as well as new initiatives to accelerate rare disease drug development, promising preclinical data for Duchenne muscular dystrophy, clinical trial progress in advanced Parkinson’s disease, and a potential new drug target for breast cancer.
The top stories:
4 November: Organ-on-a-chip, AI data, commercial strategy and IP topics unpacked
We are only a few weeks away from DDW’s Drug Discovery Innovators & Investors (DDII) UK Conference that will be held on 4 November 2026 at etc.venues Monument, London. Register today to secure early bird rates.
View the agenda and register now…
FDA launches initiative to accelerate rare disease drugs
The US Food and Drug Administration (FDA), a division within the US Department of Health and Human Services (HHS), has announced the Rare Disease Framework Initiative to accelerate the development of drugs and biologics for rare diseases.
Sapreme shares “unprecedented” preclinical data for Duchenne candidate
Sapreme Therapeutics has shared new preclinical data from its lead Duchenne muscular dystrophy (DMD) programme, SPM-2551, at the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), taking place in Denver, Colorado, US.
Phase Ib data in advanced Parkinson’s disease released as Phase II trial begins
Lundbeck has announced results from an open-label Phase Ib trial evaluating Lu AF28996, a novel, investigational, oral prodrug of D1-like/D2-like dopamine receptor agonist, in people with advanced Parkinson’s disease experiencing motor symptoms sub-optimally controlled despite optimised non-invasive antiparkinsonian medication.
Breast cancer study uncovers potential new drug target
Scientists have uncovered a previously unknown mechanism that helps breast cancer cells survive the intense stresses of being malignant, revealing a promising new target for future cancer therapies.
